The DOI matches its Crossref record.
Emergence of Mycobacterium tuberculosis with Extensive Resistance to Second-Line Drugs--Worldwide, 2000-2004: (566482006-002)
Abstract
During the 1990s, multidrug-resistant (MDR) tuberculosis (TB), defined as resistance to at least isoniazid and rifampin, emerged as a threat to TB control, both in the United States and worldwide. MDR TB treatment requires the use of second-line drugs (SLDs) that are less effective, more toxic, and costlier than first-line isoniazid- and rifampin-based regimens. In 2000, the Stop TB Partnership's Green Light Committee was created to increase access to SLDs worldwide while ensuring their proper use to prevent increased drug resistance. While assisting MDR TB treatment programs worldwide, the committee encountered reports of multiple cases of TB with resistance to virtually all SLDs. To assess the frequency and distribution of extensively drug-resistant (XDR) TB cases, CDC and the World Health Organization (WHO) surveyed an international network of TB laboratories. This report summarizes the results of that survey, which determined that, during 2000-2004, of 17,690 TB isolates, 20% were MDR and 2% were XDR. In addition, population-based data on drug susceptibility of TB isolates were obtained from the United States (for 1993-2004), Latvia (for 2000-2002), and South Korea (for 2004), where 4%, 19%, and 15% of MDR TB cases, respectively, were XDR. XDR TB has emerged worldwide as a threat to public health and TB control, raising concerns of a future epidemic of virtually untreatable TB. New anti-TB drug regimens, better diagnostic tests, and international standards for SLD-susceptibility testing are needed for effective detection and treatment of drug-resistant TB.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Gandhi, N. R., Moll, A., Sturm, A. W., Pawinski, R., Govender, T., Lalloo, U., Zeller, K., Andrews, J., & Friedland, G. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69573-1 · Cited by 1,732
Emergence of New Forms of Totally Drug-Resistant Tuberculosis Bacilli
Velayati, A. A., Masjedi, M. R., Farnia, P., Tabarsi, P., Ghanavi, J., ZiaZarifi, A. H., & Hoffner, S. E. (2009) · Chest · doi:10.1378/chest.08-2427 · Cited by 607
Worldwide Emergence of Extensively Drug-resistant Tuberculosis
Shah, N. S., Wright, A., Bai, G.-H., Barrera, L., Boulahbal, F., Martín-Casabona, N., Drobniewski, F., Gilpin, C., Havelková, M., Lepe, R., et al. (2007) · Emerging Infectious Diseases · doi:10.3201/eid1303.061400 · Cited by 583
Inhibition of mycolic acid transport across the Mycobacterium tuberculosis plasma membrane
Grzegorzewicz, A. E., Pham, H., Gundi, V. A. K. B., Scherman, M. S., North, E. J., Hess, T., Jones, V., Gruppo, V., Born, S. E. M., Korduláková, J., et al. (2012) · Nature Chemical Biology · doi:10.1038/nchembio.794 · Cited by 442
Sotgiu, G., Centis, R., D'Ambrosio, L., Alffenaar, J.-W. C., Anger, H. A., Caminero, J. A., Castiglia, P., De Lorenzo, S., Ferrara, G., Koh, W.-J., et al. (2012) · European Respiratory Journal · doi:10.1183/09031936.00022912 · Cited by 416
Metadata
- Venue
- PsycEXTRA Dataset
- Published
- 2006
- Volume
- 55
- Issue
- 11
- Pages
- 301-5
- OpenAlex
- W4248545381
- Cited by
- 513
- References
- 0
- Type
- dataset
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Emergence of Mycobacterium tuberculosis with Extensive Resistance to Second-Line Drugs--Worldwide, 2000-2004: (566482006-002). https://app.cochat.ai/papers/10.1037/e566482006-002
- The paper
- Emergence of Mycobacterium tuberculosis with Extensive Resistance to Second-Line Drugs--Worldwide, 2000-2004: (566482006-002). (2006). PsycEXTRA Dataset. https://doi.org/10.1037/e566482006-002
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.